Trial Profile
A Phase I Study of MK-4827 in Patients With Solid Tumor.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 18 Apr 2012 Actual patient number is 3 as reported by ClinicalTrials.gov.
- 07 Feb 2012 Planned End Date changed from 1 Feb 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
- 20 Dec 2011 Planned End Date changed from 1 Aug 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.